Wedbush Remains Sidelined on Fibrocell Science (FCSC) Following Azficel-T Program Failure

Unusual 11 Mid-Day Movers 6/8: (BSPM) (BLIN) (AHP) Higher; (FCSC) (PAY) (CATB) Lower

Biostar Pharma (Nasdaq: BSPM) 262.7% HIGHER; seeing strong gains on heavy volume Wednesday.

Bridgeline Digital Inc. (Nasdaq: BLIN) 65.0% HIGHER; announced the launch of their new iAPPS Pro product line, a Web Experience Management System catering to the mid-market and nimble enterprise companies. The SaaS-based solution offers fully integrated marketing automation, web content management and eCommerce capabilities for companies and retailers.

Fibrocell Science, Inc. (Nasdaq: FCSC) 39.7%... More

Streetinsider.com's Hot Lunchtime Reads 6/8: (VRX) (TSLA) (FFIV) (FCSC)

The following is a list of notable articles to help get you through the lunch hour:Valeant Pharma (VRX) Said to Try Restructuring Walgreens (WBA) Pact ->... More

Roth Affirms Fibrocell Science (FCSC) at 'Buy' Following Azficel-T Phase 2 Miss in Vocal Cord Scarring

Roth Capital affirms Fibrocell Science, Inc. (Nasdaq: FCSC) at Buy with a price target of $5 after the company announced that primary endpoints were not... More

Pre-Open Stock Movers 06/08: (BLIN) (GEVO) (AHP) Higher; (FCSC) (PAY) (FLXN) Lower (more...)

Today's Pre-Open Stock Movers:

Bridgeline Digital (NASDAQ: BLIN) 140% HIGHER;... More

Fibrocell Science (FCSC) Reports Azficel-T Phase 2 in Vocal Cord Scarring Missed Primary Endpoints

Fibrocell Science, Inc. (Nasdaq: FCSC) announced that the primary endpoints were not met in the Companys Phase II clinical trial of azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Fibrocell intends to focus its efforts on the development of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa and its earlier stage programs.

We are disappointed that azficel-T did not demonstrate the anticipated benefits for patients in this Phase II clinical trial. While we will continue to assess... More

Fibrocell Science (FCSC) halted with news pending

Fibrocell Science (NASDAQ: FCSC) trading halted with news pending.